Skip to main content
ENLV
NASDAQ Life Sciences

Enlivex Registers 23.3M Shares for Resale by Noteholder, Creating Potential Market Overhang

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.9
Mkt Cap
$208.54M
52W Low
$0.66
52W High
$2.1
52W Position info
36% above low
Off High info
57% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ENLV sits 36% above its 52-week low of $0.66.

Summary

Enlivex has filed an F-3 registration statement for the resale of 23.3 million ordinary shares by a selling shareholder, representing potential dilution of nearly 10% of outstanding shares.


Key Events · Financing and Capital Events · ENLV

  • Resale Registration Filed

    Enlivex has filed an F-3 registration statement for the resale of up to 23,333,333 ordinary shares by Lind Global Asset Management XIV, LLC.

  • Shares from Convertible Note

    These shares are issuable upon conversion of a Senior Secured Convertible Promissory Note, with an aggregate principal amount of $21.0 million, that was issued to the Selling Shareholder on March 23, 2026.

  • No Proceeds to Company

    The company will not receive any proceeds from the sale of these ordinary shares; all net proceeds will go to the Selling Shareholder.

  • Significant Potential Dilution

    The 23,333,333 shares registered for resale represent approximately 9.68% of the 241,048,724 ordinary shares outstanding as of April 17, 2026, creating a substantial potential market overhang.


Analysis · ENLV · Life Sciences

This F-3 filing registers 23,333,333 ordinary shares for resale by Lind Global Asset Management XIV, LLC, the holder of a Senior Secured Convertible Promissory Note issued on March 23, 2026. While the original debt financing was previously disclosed, this registration formalizes the mechanism for the noteholder to convert and sell shares, creating a significant potential overhang on the stock. The company will not receive any proceeds from these sales. The potential dilution from these shares represents approximately 9.68% of the company's currently outstanding shares, which is a substantial amount and could lead to selling pressure.

At the time of this filing, ENLV was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $208.5M. The 52-week trading range was $0.66 to $2.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENLV - Latest Insights

ENLV
Jul 28, 2026, 4:40 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.30
Real-time Price: $2.49 info
Change: +$0.1901 (+8%) info
Market Cap: $37.704M info
ENLV
Jul 28, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.47
Real-time Price: $2.49 info
Change: -$0.980 (-28%) info
Market Cap: $37.704M info
ENLV
Jul 28, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $3.47
Real-time Price: $2.49 info
Change: -$0.980 (-28%) info
Market Cap: $37.704M info
ENLV
Jul 20, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $2.49 info
Change: -$2.52 (-50%) info
Market Cap: $37.704M info
ENLV
Jul 13, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.68
Real-time Price: $2.49 info
Change: -$5.19 (-68%) info
Market Cap: $37.704M info